HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio From Merck
News Jul 11, 2012
The Netherlands Cancer Institute is a co-owner of patents and applications in this portfolio.
TJ Johnson, CEO of HTG Molecular Diagnostics, states, "The ability to accurately, quickly, and locally assess a patient's likelihood to have recurrent breast cancer will help improve patient care in the era of personalized medicine. Most breast cancer risk testing is currently run at a few specialty laboratories which often take weeks to return results to treating physicians and nervous patients. As part of our IVD pipeline development, HTG Molecular Diagnostics intends to pursue FDA approvals for tests that provide compelling medical value and to make those standardized tests available to local laboratories via proprietary automation and content. This patent portfolio license from Merck gives HTG access to key intellectual property to bring valuable breast cancer tests to market."
Should Historic Doping Issues Strip All Athletes of World Records?News
A proposal had been put forward by the European Athletics Council to disregard all world records set before 2005 due to issues with doping. However, a recent publication suggests these plans should be abolished.READ MORE
Some Immune Cells May Help Tumors Instead of Destroying ThemNews
New data shows that neutrophils promote tumor progression and can actually hamper the work of immunotherapy in lung cancer.READ MORE
Cancer Gene Plays Key Role in Cystic Fibrosis Lung InfectionsNews
Recent findings explain why people with cystic fibrosis are particularly prone to respiratory infections—and suggest a new approach to treatment.READ MORE